HC Wainwright Reiterates Buy Rating on Galectin Therapeutics
HC Wainwright maintains its optimistic outlook on Galectin Therapeutics with a reiterated buy rating and a price target of $11, a 165.69% upside from the current price.
Key Points
- HC Wainwright reiterated its buy rating on Galectin Therapeutics Inc. (NasdaqCM: GALT) with a price target of $11 on June 23, 2026.
- HC Wainwright's $11 price target implies 165.69% upside from Galectin Therapeutics Inc.'s ($GALT) current $4.14 share price.
- Shares of Galectin Therapeutics traded near $4.14 on Friday, with a market cap of approximately $278.6 million.
- Vanguard Capital Management opened a new position in Galectin, while Marshall Wace increased its stake by 617,778 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 23, 2026, HC Wainwright reiterated its buy rating on Galectin Therapeutics Inc. (NasdaqCM: GALT), maintaining a price target of $11. Shares of Galectin traded at about $4.14 on Friday.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Galectin Therapeutics
Vanguard Capital Management LLC opened a new position in Galectin Therapeutics, acquiring 1,966,542 shares valued at approximately $5.49 million. Marshall Wace, LLP significantly increased its holdings by 617,778 shares, resulting in a total of 1,219,912 shares worth about $3.40 million, marking a 102.6% increase. Meanwhile, Osaic Holdings, Inc. added 32,080 shares to its position, bringing its total to 1,122,670 shares valued at $3.13 million, a 2.9% increase. BlackRock, Inc. also increased its stake slightly by 2,679 shares, ending with 799,237 shares worth approximately $2.23 million. Lastly, Millennium Management LLC boosted its holdings by 562,926 shares, a 239% increase, to end with 798,434 shares valued at $2.23 million.
Galectin Therapeutics Inc. Stock Up 3.0%
Shares of NasdaqCM:GALT traded near $4.14 on Friday. Galectin Therapeutics Inc. has a market cap of about $278.6 million. The stock has experienced a 52-week low of $2.03 and a high of $7.13. Its 50-day moving average stands at $2.48, while the 200-day moving average is $3.72. The company has a current ratio of 2.15 and a quick ratio of 1.93.
$GALT price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Galectin Therapeutics Inc.
On June 23, 2026, Jamil Khurram, the Chief Medical Officer, was involved in several transactions. He sold 7,557 shares at an average price of $3.14 under a planned Rule 10b5-1 sale. On the same day, he also purchased 7,557 shares at $1.23 in an unplanned transaction. Additionally, on May 26, 2026, Khurram sold 568 shares at $3.10 under a planned sale and bought 568 shares at $1.23 in an unplanned transaction.
Analysts Set New Price Targets
On June 23, 2026, HC Wainwright & Co. reiterated its buy rating on Galectin Therapeutics with a price target of $11. The firm has consistently maintained a buy rating on the stock in previous assessments. Currently, the consensus among analysts is a buy rating with a mean target price of $11.
About Galectin Therapeutics
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Norcross, Georgia. It focuses on developing therapies for fibrotic diseases and cancer. The company's lead product candidate is belapectin (GR-MD-02), which is a galectin-3 inhibitor currently in Phase 2 clinical trials for patients with advanced fibrosis and compensated cirrhosis. Founded in 2000, Galectin Therapeutics operates with a small team under the leadership of CEO Joel Lewis.
Bottom Line
HC Wainwright's reiterated buy rating and $11 price target for Galectin Therapeutics reflect continued optimism about the company's potential. Shares of Galectin have fluctuated within a broad range over the past year, reflecting both investor interest and market volatility. Investors keep a close watch on such analyst ratings and institutional activities to gauge market sentiment, though these backward-looking reports may not indicate current positions or future performance.
Get Galectin Therapeutics Inc. alerts
New 13F filings, insider trades, and analyst moves on $GALT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.